636 results on '"Del Mastro, A."'
Search Results
2. Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer
- Author
-
Marco Tagliamento, Alessandra Gennari, Matteo Lambertini, Ramon Salazar, Nadia Harbeck, Lucia Del Mastro, Juan Aguilar-Company, Mark Bower, Rachel Sharkey, Alessia Dalla Pria, Andrea Plaja, Amanda Jackson, Jasmine Handford, Ailsa Sita-Lumsden, Clara Martinez-Vila, Marta Matas, Ana Miguel Rodriguez, Bruno Vincenzi, Giuseppe Tonini, Alexia Bertuzzi, Joan Brunet, Paolo Pedrazzoli, Francesca D'Avanzo, Federica Biello, Alasdair Sinclair, Alvin J.X. Lee, Sabrina Rossi, Gianpiero Rizzo, Oriol Mirallas, Isabel Pimentel, Maria Iglesias, Ana Sanchez de Torre, Annalisa Guida, Rossana Berardi, Alberto Zambelli, Carlo Tondini, Marco Filetti, Francesca Mazzoni, Uma Mukherjee, Nikolaos Diamantis, Alessandro Parisi, Avinash Aujayeb, Aleix Prat, Michela Libertini, Salvatore Grisanti, Maura Rossi, Federica Zoratto, Daniele Generali, Cristina Saura, Gary H. Lyman, Nicole M. Kuderer, David J. Pinato, and Alessio Cortellini more...
- Subjects
Cancer Research ,breast cancer ,Oncology ,cancers ,COVID-19 outcomes - Abstract
PURPOSE Although representing the majority of newly diagnosed cancers, patients with breast cancer appear less vulnerable to COVID-19 mortality compared with other malignancies. In the absence of patients on active cancer therapy included in vaccination trials, a contemporary real-world evaluation of outcomes during the various pandemic phases, as well as of the impact of vaccination, is needed to better inform clinical practice. METHODS We compared COVID-19 morbidity and mortality among patients with breast cancer across prevaccination (February 27, 2020-November 30, 2020), Alpha-Delta (December 1, 2020-December 14, 2021), and Omicron (December 15, 2021-January 31, 2022) phases using OnCovid registry participants (ClinicalTrials.gov identifier: NCT04393974 ). Twenty-eight-day case fatality rate (CFR28) and COVID-19 severity were compared in unvaccinated versus double-dosed/boosted patients (vaccinated) with inverse probability of treatment weighting models adjusted for country of origin, age, number of comorbidities, tumor stage, and receipt of systemic anticancer therapy within 1 month of COVID-19 diagnosis. RESULTS By the data lock of February 4, 2022, the registry counted 613 eligible patients with breast cancer: 60.1% (n = 312) hormone receptor–positive, 25.2% (n = 131) human epidermal growth factor receptor 2–positive, and 14.6% (n = 76) triple-negative. The majority (61%; n = 374) had localized/locally advanced disease. Median age was 62 years (interquartile range, 51-74 years). A total of 193 patients (31.5%) presented ≥ 2 comorbidities and 69% (n = 330) were never smokers. In total, 392 (63.9%), 164 (26.8%), and 57 (9.3%) were diagnosed during the prevaccination, Alpha-Delta, and Omicron phases, respectively. Analysis of CFR28 demonstrates comparable estimates of mortality across the three pandemic phases (13.9%, 12.2%, 5.3%, respectively; P = .182). Nevertheless, a significant improvement in outcome measures of COVID-19 severity across the three pandemic time periods was observed. Importantly, when reported separately, unvaccinated patients from the Alpha-Delta and Omicron phases achieved comparable outcomes to those from the prevaccination phase. Of 566 patients eligible for the vaccination analysis, 72 (12.7%) were fully vaccinated and 494 (87.3%) were unvaccinated. We confirmed with inverse probability of treatment weighting multivariable analysis and following a clustered robust correction for participating center that vaccinated patients achieved improved CFR28 (odds ratio [OR], 0.19; 95% CI, 0.09 to 0.40), hospitalization (OR, 0.28; 95% CI, 0.11 to 0.69), COVID-19 complications (OR, 0.16; 95% CI, 0.06 to 0.45), and reduced requirement of COVID-19–specific therapy (OR, 0.24; 95% CI, 0.09 to 0.63) and oxygen therapy (OR, 0.24; 95% CI, 0.09 to 0.67) compared with unvaccinated controls. CONCLUSION Our findings highlight a consistent reduction of COVID-19 severity in patients with breast cancer during the Omicron outbreak in Europe. We also demonstrate that even in this population, a complete severe acute respiratory syndrome coronavirus 2 vaccination course is a strong determinant of improved morbidity and mortality from COVID-19. more...
- Published
- 2023
- Full Text
- View/download PDF
Catalog
3. Abstract P1-11-04: Assessing the clinico-pathological characteristics of HER2 positive metastatic breast cancer patients experiencing radiologic complete response in a nationwide cohort
- Author
-
Linda Cucciniello, Eva Blondeaux, Claudia Bighin, Simona Gasparro, Stefania Russo, Arianna Dri, Palma Pugliese, Andrea Fontana, Giuseppe Naso, Antonella Ferzi, Ferdinando Riccardi, Valentina Sini, Luca Boni, Alessandra Fabi, Filippo Montemurro, Michelino De Laurentiis, Grazia Arpino, Lucia Del Mastro, Lorenzo Gerratana, and Fabio Puglisi more...
- Subjects
Cancer Research ,Oncology - Abstract
Background: Up to 6% of patients (pts) with HER2 positive (pos) metastatic breast cancer (MBC) experience a radiologic complete response (rCR) to a first line of therapy, but these results mostly derive from dated and/or limited cohorts. Aim of this study was to define the clinico-pathological characteristics of HER2 positive (pos) MBC pts experiencing a rCR. Methods: Pts were selected from the database of the GIM14 study (NCT02284581) and classified according to the best radiologic response obtained to the first line chemotherapy (CT) and upon time-to-treatment-failure (TTF). rCR was defined as complete response (CR) with a TTF > 3 months. The association across variables was tested through logistic regression and their prognostic impact in terms of overall survival (OS) was estimated using the Kaplan-Meier method and compared using the log-rank test. Results: Of the 3,423 pts included in the GIM14 study, 814 had HER2 pos MBC. After exclusion of pts treated with first line endocrine therapy and/or with TTF < 3 months, 656 pts were included in the present analysis, of which 96 (14.6%) experienced a rCR. Instead, the best response was a partial response for 295 pts (45.0%), stable disease for 221 pts (33.7%), and progression for 44 pts (6.7%). Most pts (59.8%) presented de novo MBC; 379 pts (57.8%) had visceral metastases (mets), 609 pts (92.8%) did not have central nervous system (CNS) involvement and 318 pts (48.5%) had only 1 site of distant mets. Also, 445 pts (67.9%) had hormone receptor (HR) pos disease, a HER2 3+ score at immunohistochemistry (IHC) was present in 59.8% of cases versus 40.2% with HER2 2+ at IHC and in situ hybridization (ISH) + disease. Taxanes were the main CT backbone (489 pts, 74.5%), 341 pts (52.0%) had received a Trastuzumab-Pertuzumab doublet. At multivariable analysis, higher odds of experiencing a rCR were reported for presence of non-visceral mets (OR 1.87, 95%CI 1.10-3.17), low number of metastatic sites (OR 2.42, 95%CI 0.80-7.33 for 1 site only) and HER2 3+ score at IHC (OR 1.80, 95%CI 1.09-2.98). Disease-free interval (DFI) was associated to rCR at univariable but not at multivariable analysis. HR status, CT backbone and type of anti-HER2 regimen were not associated with rCR neither at univariable nor at multivariable analysis. Median follow-up was 76.2 months. Amongst pts with TTF>12 months, those with rCR had a significantly higher OS compared to those not experiencing a rCR (median OS 133 and 90 months, respectively; p=0.0191). OS rates in pts with TTF ≥ 12 months were 97.8% at 2-year follow-up and 59.4% at 5-year follow-up. Instead, in pts with TTF ≥ 60 months, OS rates were 76.7% at 10-year follow-up. Amongst the 96 pts experiencing a CR, 38 had a rCR with TTF between 12 and 60 months, while 22 pts had a rCR with a TTF ≥ 60 months. The remaining pts had a CR with a TTF < 12 months. Pts with HR negative (neg) disease were found to be more likely to experience a rCR with a with TTF between 12 and 60 months, whilst pts with HR pos disease had a higher probability to experience a rCR with a TTF ≥ 60 months (p=0.0074). Pts with HER2 3+ score at IHC had a higher probability to achieve a rCR with a TTF ≥ 12 months compared to pts with HER2 2+ score at IHC and ISH + (p=0.0216). Age at diagnosis, menopausal status, DFI, number and site of mets, CT backbone and anti-HER2 therapy did not influence the duration of the rCR obtained. Conclusions: This study characterized a real-world cohort of HER2 positive MBC patients experiencing radiologic complete response to a first line treatment. Based on these results a clinical trial focused on liquid biopsy-based minimal residual disease is being designed. Novel anti-HER2 agents are gaining momentum as ever increasingly effective treatments and future de-escalation strategies after complete response will represent a growing need. Citation Format: Linda Cucciniello, Eva Blondeaux, Claudia Bighin, Simona Gasparro, Stefania Russo, Arianna Dri, Palma Pugliese, Andrea Fontana, Giuseppe Naso, Antonella Ferzi, Ferdinando Riccardi, Valentina Sini, Luca Boni, Alessandra Fabi, Filippo Montemurro, Michelino De Laurentiis, Grazia Arpino, Lucia Del Mastro, Lorenzo Gerratana, Fabio Puglisi. Assessing the clinico-pathological characteristics of HER2 positive metastatic breast cancer patients experiencing radiologic complete response in a nationwide cohort [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P1-11-04. more...
- Published
- 2023
- Full Text
- View/download PDF
4. Abstract GS1-09: Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
- Author
-
Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun Sheng Huang, Jens Huober, Georgina Garnica Jaliffe, Irfan Cicin, Sara Tolaney, Matthew P. Goetz, Hope Rugo, Elżbieta Senkus, Laura Testa, Lucia Del Mastro, Chikako Shimizu, Ran Wei, Ashwin Shahir, Maria Munoz, Belen San Antonio, Valerie Andre, Nadia Harbeck, and Miguel Martín more...
- Subjects
Cancer Research ,Oncology - Abstract
Background Adjuvant abemaciclib (a CDK4 and 6 inhibitor) combined with ET resulted in significant and clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in patients (pts) with HR+, HER2-, node-positive, high risk EBC in the monarchE trial, and is an approved adjuvant therapy for these patients. Here we present efficacy results from a pre-specified overall survival interim analysis (OS IA2) which was planned to occur 2 years (yrs) after the primary outcome analysis. Methods Pts were randomized (1:1) to receive ET for up to 10 yrs +/- abemaciclib for 2 yrs (study treatment period). High-risk EBC was defined as either ≥4 positive axillary lymph nodes (ALN), or 1-3 ALN with either Grade 3 disease and/or tumor ≥5 cm (Cohort 1). While the proliferation biomarker Ki-67 was centrally assessed in all pts with available tissue sample, an additional smaller group of pts with 1-3+ ALN and central Ki-67 ≥20% as the only high-risk feature were included (Cohort 2). The intent-to-treat (ITT) population consisted of both Cohort 1 (5120 pts) and Cohort 2 (517 pts). Hazard ratios (HR) were estimated using Cox proportional hazard model. Results At a median follow-up of 42 months, all pts were off abemaciclib. IDFS and DRFS data illustrate a sustained benefit beyond the treatment period. In the ITT population, the HR for IDFS was 0.664 (95% CI: 0.578, 0.762) and DRFS was 0.659 (95% CI: 0.567, 0.767). At 4 yrs, this reflected an improvement in IDFS rates from 79.4% to 85.8% (absolute difference 6.4%), and in DRFS rates from 82.5% to 88.4% (absolute difference 5.9%). The continued separation of the curves was associated with an increase in absolute benefit in IDFS 4-year rates compared to 2-and 3-year IDFS rates (absolute difference 2.8% and 4.8% respectively). While OS remained immature, there was a lower number of deaths observed in the abemaciclib plus ET arm compared to the ET alone arm (157 [5.6%] vs 173 [6.1%], HR 0.929 [95% CI: 0.748, 1.153], p = 0.503), suggesting that the robust benefit in IDFS and DRFS began to translate into a numerically favorable OS HR. As previously described, within Cohort 1, a Ki-67 index of ≥20% was associated with a worse prognosis, but similar abemaciclib treatment effects were observed regardless of Ki-67 index. No new safety signals were observed. Conclusion The clinically meaningful benefit of adjuvant abemaciclib added to ET in HR+, HER2-, node-positive, high-risk EBC persists beyond completion of abemaciclib therapy, yielding an increase in absolute IDFS and DRFS benefit at 4 yrs. While OS remains immature at this time, the lower number of deaths in the abemaciclib arm compared to the ET arm suggest that a survival signal favoring abemaciclib is emerging. Citation Format: Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy, Priya Rastogi, Mario Campone, Patrick Neven, Chiun Sheng Huang, Jens Huober, Georgina Garnica Jaliffe, Irfan Cicin, Sara Tolaney, Matthew P. Goetz, Hope Rugo, Elżbieta Senkus, Laura Testa, Lucia Del Mastro, Chikako Shimizu, Ran Wei, Ashwin Shahir, Maria Munoz, Belen San Antonio, Valerie Andre, Nadia Harbeck, Miguel Martín. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr GS1-09. more...
- Published
- 2023
- Full Text
- View/download PDF
5. Vaginal oxygen plus hyaluronic acid on genito-urinary symptoms of breast cancer survivors
- Author
-
C. Massarotti, G. Asinaro, M. G. Schiaffino, C. Ronzini, I. Vacca, M. Lambertini, P. Anserini, L. Del Mastro, and A. Cagnacci
- Subjects
Obstetrics and Gynecology ,General Medicine - Published
- 2023
- Full Text
- View/download PDF
6. MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology
- Author
-
Ankit K. Dutta, Jean-Baptiste Alberge, Elizabeth D. Lightbody, Cody J. Boehner, Andrew Dunford, Romanos Sklavenitis-Pistofidis, Tarek H. Mouhieddine, Annie N. Cowan, Nang Kham Su, Erica M. Horowitz, Hadley Barr, Laura Hevenor, Jenna B. Beckwith, Jacqueline Perry, Amanda Cao, Ziao Lin, Frank K. Kuhr, Richard G. Del Mastro, Omar Nadeem, Patricia T. Greipp, Chip Stewart, Daniel Auclair, Gad Getz, and Irene M. Ghobrial more...
- Subjects
Oncology - Abstract
Abstract Multiple myeloma (MM) develops from well-defined precursor stages; however, invasive bone marrow (BM) biopsy limits screening and monitoring strategies for patients. We enumerated circulating tumor cells (CTC) from 261 patients (84 monoclonal gammopathy of undetermined significance, 155 smoldering multiple myeloma, and 22 MM), with neoplastic cells detected in 84%. We developed a novel approach, MinimuMM-seq, which enables the detection of translocations and copy-number abnormalities through whole-genome sequencing of highly pure CTCs. Application to CTCs in a cohort of 51 patients, 24 with paired BM, was able to detect 100% of clinically reported BM biopsy events and could replace molecular cytogenetics for diagnostic yield and risk classification. Longitudinal sampling of CTCs in 8 patients revealed major clones could be tracked in the blood, with clonal evolution and shifting dynamics of subclones over time. Our findings provide proof of concept that CTC detection and genomic profiling could be used clinically for monitoring and managing disease in MM. Significance: In this study, we established an approach enabling the enumeration and sequencing of CTCs to replace standard molecular cytogenetics. CTCs harbored the same pathognomonic MM abnormalities as BM plasma cells. Longitudinal sampling of serial CTCs was able to track clonal dynamics over time and detect the emergence of high-risk genetic subclones. more...
- Published
- 2023
- Full Text
- View/download PDF
7. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
- Author
-
Stephen R D, Johnston, Masakazu, Toi, Joyce, O'Shaughnessy, Priya, Rastogi, Mario, Campone, Patrick, Neven, Chiun-Sheng, Huang, Jens, Huober, Georgina Garnica, Jaliffe, Irfan, Cicin, Sara M, Tolaney, Matthew P, Goetz, Hope S, Rugo, Elzbieta, Senkus, Laura, Testa, Lucia, Del Mastro, Chikako, Shimizu, Ran, Wei, Ashwin, Shahir, Maria, Munoz, Belen, San Antonio, Valérie, André, Nadia, Harbeck, and Miguel, Martin more...
- Subjects
Oncology - Abstract
Adjuvant abemaciclib plus endocrine therapy previously showed a significant improvement in invasive disease-free survival and distant relapse-free survival in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2; also known as ERBB2)-negative, node-positive, high-risk, early breast cancer. Here, we report updated results from an interim analysis to assess overall survival as well as invasive disease-free survival and distant relapse-free survival with additional follow-up.In monarchE, an open-label, randomised, phase 3 trial, adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence with an Eastern Cooperative Oncology Group performance status of 0 or 1 were recruited from 603 sites including hospitals and academic and community centres in 38 countries. Patients were randomly assigned (1:1) by means of an interactive web-based response system (block size of 4), stratified by previous chemotherapy, menopausal status, and region, to receive standard-of-care endocrine therapy of physician's choice for up to 10 years with or without abemaciclib 150 mg orally twice a day for 2 years (treatment period). All therapies were administered in an open-label manner without masking. High-risk disease was defined as either four or more positive axillary lymph nodes, or between one and three positive axillary lymph nodes and either grade 3 disease or tumour size of 5 cm or larger (cohort 1). A smaller group of patients were enrolled with between one and three positive axillary lymph nodes and Ki-67 of at least 20% as an additional risk feature (cohort 2). This was a prespecified overall survival interim analysis planned to occur 2 years after the primary outcome analysis for invasive disease-free survival. Efficacy was assessed in the intention-to-treat population. Safety was assessed in all treated patients. The study is registered with ClinicalTrials.gov, NCT03155997, and is ongoing.Between July 17, 2017, and Aug 12, 2019, 5637 patients were randomly assigned (5601 [99·4%] were women and 36 [0·6%] were men). 2808 were assigned to receive abemaciclib plus endocrine therapy and 2829 were assigned to receive endocrine therapy alone. At a median follow-up of 42 months (IQR 37-47), median invasive disease-free survival was not reached in either group and the invasive disease-free survival benefit previously reported was sustained: HR 0·664 (95% CI 0·578-0·762, nominal p0·0001). At 4 years, the absolute difference in invasive disease-free survival between the groups was 6·4% (85·8% [95% CI 84·2-87·3] in the abemaciclib plus endocrine therapy group vs 79·4% [77·5-81·1] in the endocrine therapy alone group). 157 (5·6%) of 2808 patients in the abemaciclib plus endocrine therapy group died compared with 173 (6·1%) of 2829 patients in the endocrine therapy alone group (HR 0·929, 95% CI 0·748-1·153; p=0·50). The most common grade 3-4 adverse events were neutropenia (in 548 [19·6%] of 2791 patients receiving abemaciclib plus endocrine therapy vs 24 [0·9%] of 2800 patients in the endocrine therapy alone group), leukopenia (318 [11·4%] vs 11 [0·4%]), and diarrhoea (218 [7·8%] vs six [0·2%]). Serious adverse events occurred in 433 (15·5%) of 2791 patients receiving abemaciclib plus endocrine therapy versus 256 (9·1%) of 2800 receiving endocrine therapy. There were two treatment-related deaths in the abemaciclib plus endocrine therapy group (diarrhoea and pneumonitis) and none in the endocrine therapy alone group.Adjuvant abemaciclib reduces the risk of recurrence. The benefit is sustained beyond the completion of treatment with an absolute increase at 4 years, further supporting the use of abemaciclib in patients with high-risk hormone receptor-positive, HER2-negative early breast cancer. Further follow-up is needed to establish whether overall survival can be improved with abemaciclib plus endocrine therapy in these patients.Eli Lilly. more...
- Published
- 2023
- Full Text
- View/download PDF
8. Dimensiones de la interacción e importancia del diálogo en la relación docente-estudiante
- Author
-
Oscar Sumar and Fernando Del Mastro
- Subjects
Law ,Education - Abstract
En este trabajo analizamos las vivencias y opiniones de un grupo de docentes de Derecho acerca de la interacción con sus estudiantes. Buscamos dar cuenta de qué dimensiones de la interacción son enfocadas por los docentes, en contraste con aquellas resaltadas por los estudiantes en una investigación previa. Los resultados muestran que los docentes enfatizan la dimensión pedagógica de la interacción, mientras que los estudiantes ponen más énfasis en la dimensión intersubjetiva. Asimismo, advertimos contrastes en temas como la opinión acerca de la participación estudiantil o las características que hacen reconocible a un profesor y un alumno. Abordamos también la dimensión regulatoria de la interacción en problemas como el plagio. Los docentes suelen operar con una lógica conductista (castigos, refuerzos) y enfocados en lo pedagógico (cambiar tipos de evaluación para evitar que los alumnos se copien). En los diversos puntos de esta investigación se muestra la ausencia del diálogo (tanto en lo presencial como lo virtual) como vía para comprender la vivencia y opinión del otro y, sobre esa base, fortalecer la interacción y lidiar con las problemáticas que surgen en las clases. more...
- Published
- 2022
- Full Text
- View/download PDF
9. Pensar y sentir de estudiantes de derecho en su contacto con el mundo profesional
- Author
-
Fernando Del Mastro Puccio
- Subjects
General Medicine - Abstract
En el Perú, quienes estudian la carrera de derecho deben completar un periodo de prácticas preprofesionales. Pese a la relevancia que tienen estas experiencias como primer contacto con la realidad del ejercicio profesional, no se ha investigado cuál es su impacto en la formación de los estudiantes. En este artículo, a partir de un marco teórico centrado en Hannah Arendt y del análisis narrativo de relatos de estudiantes, se busca comprender cómo operan los pensamientos congelados en sus experiencias como practicantes preprofesionales.A partir del análisis, se han identificado los siguientes pensamientos congelados: (i) trabajar en exceso es necesario para aprender, (ii) el maltrato es válido si les ocurre a todos y (iii) el propio rol consiste en cumplir los encargos sin pensar ni cuestionar. Aunque estos pensamientos son transmitidos a los estudiantes en situaciones de incumplimiento legal, maltrato y comisión de faltas éticas, suelen actuar conforme a lo esperado sin decir ni hacer algo. Predomina el miedo a no ser valorados y se deja de lado cualquier proceso de reflexión donde puedan cuestionar lo que les indican. Hay, sin embargo, casos donde los estudiantes dudan de si tales pensamientos son correctos, pero el conflicto interno queda sin resolver.La relevancia de este trabajo radica en mostrar parte de lo que acontece en un ámbito formativo que tiene gran impacto en el aprendizaje, pero que ha sido desatendido. Particularmente, muestra modos en los que factores anímicos, como el deseo de ser reconocido y la duda respecto a la propia valía, funcionan como barreras en los procesos de pensamiento y acción. Finalmente, a nivel de reflexión pedagógica, se presenta a la pedagogía socrática como aproximación que puede tener buenos resultados a nivel de la formación ética de estudiantes que viven situaciones como las analizadas. more...
- Published
- 2022
- Full Text
- View/download PDF
10. Supplementary Figures and Tables from MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology
- Author
-
Irene M. Ghobrial, Gad Getz, Daniel Auclair, Chip Stewart, Patricia T. Greipp, Omar Nadeem, Richard G. Del Mastro, Frank K. Kuhr, Ziao Lin, Amanda Cao, Jacqueline Perry, Jenna B. Beckwith, Laura Hevenor, Hadley Barr, Erica M. Horowitz, Nang Kham Su, Annie N. Cowan, Tarek H. Mouhieddine, Romanos Sklavenitis-Pistofidis, Andrew Dunford, Cody J. Boehner, Elizabeth D. Lightbody, Jean-Baptiste Alberge, and Ankit K. Dutta more...
- Abstract
Supplementary data contains additional Materials and Methods used to generate results presented only in the supplementary figures and tables, as well as more detailed bioinformatics methods. Figure S1 shows correlation between clinical measures of disease pathology, survival, and circulating tumor cells enumeration. Figure S2 shows characteristics of isolated circulating tumor cells from peripheral blood of precursor disease patients. Figure S3 shows cohort-level genomic characterization of tumor in MM precursor stages with CTCs. Figure S4 shows longitudinal and tissue-matched genomic characterization of driver mutations. Figure S5 shows comparison of mutational processes between BMPCs and CTCs assigned to most likely PCAWG composite reference signature. Table S1 shows clinical characteristics and sampling of participants in this study. Table S2 shows whole-genome sequencing coverage and library metrics. Table S3 shows clinical BM FISH results and cells recovered for cohort with matched samples. Table S4 shows comparison of BCR sequence between BMPCs and CTCs. Table S5 shows clinical BM FISH results of peripheral blood only cohort and CTCs recovered. Table S6 shows enumeration of single nucleotide variants and short insertions and deletions discovered from WGS of CTCs. Table S7 shows enumeration of structural variants reconstructed from WGS of CTCs. more...
- Published
- 2023
- Full Text
- View/download PDF
11. Data from MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology
- Author
-
Irene M. Ghobrial, Gad Getz, Daniel Auclair, Chip Stewart, Patricia T. Greipp, Omar Nadeem, Richard G. Del Mastro, Frank K. Kuhr, Ziao Lin, Amanda Cao, Jacqueline Perry, Jenna B. Beckwith, Laura Hevenor, Hadley Barr, Erica M. Horowitz, Nang Kham Su, Annie N. Cowan, Tarek H. Mouhieddine, Romanos Sklavenitis-Pistofidis, Andrew Dunford, Cody J. Boehner, Elizabeth D. Lightbody, Jean-Baptiste Alberge, and Ankit K. Dutta more...
- Abstract
Multiple myeloma (MM) develops from well-defined precursor stages; however, invasive bone marrow (BM) biopsy limits screening and monitoring strategies for patients. We enumerated circulating tumor cells (CTC) from 261 patients (84 monoclonal gammopathy of undetermined significance, 155 smoldering multiple myeloma, and 22 MM), with neoplastic cells detected in 84%. We developed a novel approach, MinimuMM-seq, which enables the detection of translocations and copy-number abnormalities through whole-genome sequencing of highly pure CTCs. Application to CTCs in a cohort of 51 patients, 24 with paired BM, was able to detect 100% of clinically reported BM biopsy events and could replace molecular cytogenetics for diagnostic yield and risk classification. Longitudinal sampling of CTCs in 8 patients revealed major clones could be tracked in the blood, with clonal evolution and shifting dynamics of subclones over time. Our findings provide proof of concept that CTC detection and genomic profiling could be used clinically for monitoring and managing disease in MM.Significance:In this study, we established an approach enabling the enumeration and sequencing of CTCs to replace standard molecular cytogenetics. CTCs harbored the same pathognomonic MM abnormalities as BM plasma cells. Longitudinal sampling of serial CTCs was able to track clonal dynamics over time and detect the emergence of high-risk genetic subclones.This article is highlighted in the In This Issue feature, p. 247 more...
- Published
- 2023
- Full Text
- View/download PDF
12. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer
- Author
-
Claudia von Arx, Pietro De Placido, Aldo Caltavituro, Rossana Di Rienzo, Roberto Buonaiuto, Michelino De Laurentiis, Grazia Arpino, Fabio Puglisi, Mario Giuliano, Lucia Del Mastro, von Arx, Claudia, De Placido, Pietro, Caltavituro, Aldo, Di Rienzo, Rossana, Buonaiuto, Roberto, De Laurentiis, Michelino, Arpino, Grazia, Puglisi, Fabio, Giuliano, Mario, and Del Mastro, Lucia more...
- Subjects
Colon-rectal cancer ,Oncology ,ADC ,ADCs ,Gastric cancer ,HER2-low breast cancer ,Non-small-cell lung cancer ,Trastuzumab ,Radiology, Nuclear Medicine and imaging ,General Medicine - Abstract
A novel class of drugs, antibody-drug conjugates (ADCs), are now rapidly emerging as highly effective treatments for solid tumours. ADCs conjugate conventional chemotherapeutics with highly selective targeted monoclonal antibodies. Anti-HER2 therapies selectively target cancer cells expressing human epidermal growth factor receptor 2 (HER2), among them trastuzumab has been the first HER2-targeting monoclonal antibody to achieve successful results that made it the backbone of anti-HER2 therapies. Trastuzumab drug conjugates (T-DCs), use trastuzumab as a selective antibody to lead cytotoxic drugs inside cancer cells. Trastuzumab-emtansine (T-DM1) and trastuzumab-deruxtecan (T-Dxd) are the two approved T-DCs. T-Dxd along with other five T-DCs represents "second generation ADCs" that has been firstly tested in HER2 positive breast cancer (BC) and then in HER2-low BC and other cancers showing promising results thanks to extraordinary and innovative pharmacokinetic and pharmacodynamic characteristics. The evidence generated so far are establishing them as a completely new class of agents effective in solid cancer treatments but also warrants physicians against unconventional toxicity profiles. The role of T-DCs in HER2-positive BC has been largely reviewed, while in this review, we provided for the first time in literature an overview of trastuzumab drug conjugates (T-DCs) approved and/or in clinical development with a specific focus on their efficacy and safety profile in HER2-low BC and other solid tumours different from BC. We started by analysing T-DCs biological characteristics that underly the differences in T-DCs pharmacodynamics and safety profile, then presented the main evidence on the activity and efficacy of these emerging T-DCs in HER2-low BC and other HER2 overexpressing and/or mutated solid tumours and lastly, we provided an overview of the complex and still evolving scenario in which these compounds should be allocated. A specific focus on possible combination strategies with other drugs such as immunotherapy, chemotherapy and target therapy, to increase T-DCs activity and eventually overcome future upcoming resistance mechanisms, are here also critically reviewed. more...
- Published
- 2022
13. Ultra-Low-Profile Continuous Transverse Stub Array for SatCom Applications
- Author
-
Michele Del Mastro, Adham Mahmoud, Thomas Potelon, Ronan Sauleau, Gilles Quagliaro, Anthony Grbic, Mauro Ettorre, ANYWAVES, Institut d'Électronique et des Technologies du numéRique (IETR), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - pôle Sciences et technologie, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Direction générale de l'Armement (DGA), Thales SIX GTS France, University of Michigan System, ANR-ASTRID MATURATION (project named RAFQO), European Union through the European Regional Development Fund (ERDF), Ministry of Higher Education and Research, Brittany and Rennes Metropole through the CPER Project SOPHIE/STIC Ondes, and ANR-16-ASMA-0006,RAFQO 2016,Réseau Actif de Formateurs Quasi-Optiques(2016) more...
- Subjects
metasurface ,ultra-low profile ,[SPI]Engineering Sciences [physics] ,Satcom On-The-Move (SOTM) ,Dual-band polarizer ,printed circuit board (PCB) technology ,satellite communication (SatCom) ,periodic structures ,Electrical and Electronic Engineering ,linear-to-circular polarization (LP-to-CP) conversion ,wideband ,dual-circular polarization (CP) - Abstract
International audience; Modern K-/Ka-band satellite communications have become increasingly demanding in recent years with regard to the performance of the terminal antenna used in the link. These terminals should be high gain and broadband, as well as guarantee polarization diversity over a large field of view. A low profile is also highly desired to integrate the antenna system into a variety of moving platforms, such as aircraft and trains. An ultra-low-profile continuous transverse stub array is proposed here to tackle these challenges. The antenna array is realized in printed circuit board technology by adopting a contactless transition between the stacked-up layers without resorting to blind or buried vias. The proposed antenna is wideband (impedance matched within the 19-31 GHz band, i.e., similar to 50%) and provides multibeam radiation for polar angles as far as +/- 22.5 degrees. The peak value of the gain is 19.7 dBi, and the maximum radiation efficiency equals 50%. Furthermore, the antenna array is combined with a dual-band polarization converter. The latter provides orthogonal circular polarization (CP) in two non-adjacent bands. The overall antenna system performs right- and left-hand CPs within the SatCom downlink and uplink in the K-/Ka-band, respectively. For each polarization, the axial ratio is below 3 dB over 9.47% and 4.42% fractional bandwidths, respectively. more...
- Published
- 2022
- Full Text
- View/download PDF
14. Abstract PD10-06: Predictive value of RT-qPCR 27-gene IO score and comparison with RNA-Seq IO score in the NeoTRIPaPDL1 trial
- Author
-
Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Robert S. Seitz, Tyler J. Nielsen, Marc Thill, Antonio Anton, Stefania Russo, Eva Maria Ciruelos, Brock L. Schweitzer, Douglas T. Ross, Barbara Galbardi, Richard Greil, Vladimir Semiglazov, Balázs Gyorffy, Marco Colleoni, Catherine Kelly, Gabriella Mariani, Lucia Del Mastro, Pinuccia Valagussa, Giuseppe Viale, Maurizio Callari, Luca Gianni, and Giampaolo Bianchini more...
- Subjects
Cancer Research ,Oncology - Abstract
Background The identification of biomarkers for optimization of immune checkpoint inhibitors (ICI) treatment is an unmet clinical need. In the Phase III randomized trial, NeoTRIPaPDL1, a post-hoc analysis of whole transcriptome RNA-Seq data, previously showed that the 27-gene IO score is a potential predictive biomarker of increased pathological complete response with the addition of atezolizumab to carboplatin/nab-paclitaxel (Bianchini G ESMO 2021). However, the laboratory implementation of gene-expression signatures measured using RNA-seq is challenging. Therefore, we further assessed the predictive value of the IO score using a twenty-seven gene RT-qPCR assay on NeoTRIP samples, and compared to the previously reported RNA-Seq version of the assay. Methods The NeoTRIP study randomized patients to eight cycles of carboplatin/nab-paclitaxel (CT) with or without atezolizumab (CT/A). 258 patients were evaluable for pCR (breast and nodes) as Per-Protocol Population. We assessed the IO score as binary and continuous variables using the CAP/CLIA validated DetermaIO qPCR test (Saltman et al 2021) on pre-treatment core biopsies (n=220/258; 85.3%), all of which have RNA-Seq data available. We evaluated the association between IO score defined by RT-qPCR and RNA-Seq, and the association of the IO score defined by RT-qPCR test with PD-L1 IHC (Ventana SP142), stromal TILs (sTILs), and pCR. Results Comparison of continuous IO scores between the RT-qPCR assay and the RNA-Seq algorithm had a Pearson’s correlation of 0.94 (p < 0.0001). High agreement between categorical IO scores was also observed (Cohens’ kappa = 0.84; 95% confidence interval [CI] = 0.77-0.91; p < 0.0001). RT-qPCR IO score was balanced in the two arms (p = 0.65) with 44% and 40% positive patients in the CT and CT/A arms, respectively. The RT-qPCR IO score was correlated with both PD-L1 (Pearson’s r = 0.64; p < 0.0001) and sTILs (Pearson’s r = 0.67; p < 0.0001). Continuous IO score was significantly predictive of pCR in CT/A (Odds ratio [OR] = 3.12; 95% CI = 1.20-8.10; p Citation Format: Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Robert S. Seitz, Tyler J. Nielsen, Marc Thill, Antonio Anton, Stefania Russo, Eva Maria Ciruelos, Brock L. Schweitzer, Douglas T. Ross, Barbara Galbardi, Richard Greil, Vladimir Semiglazov, Balázs Gyorffy, Marco Colleoni, Catherine Kelly, Gabriella Mariani, Lucia Del Mastro, Pinuccia Valagussa, Giuseppe Viale, Maurizio Callari, Luca Gianni, Giampaolo Bianchini. Predictive value of RT-qPCR 27-gene IO score and comparison with RNA-Seq IO score in the NeoTRIPaPDL1 trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD10-06. more...
- Published
- 2022
- Full Text
- View/download PDF
15. Abstract P4-11-20: Attitudes and factors influencing contraception use over time in premenopausal women with early breast cancer in the prospective CANTO study
- Author
-
Matteo Lambertini, Claudia Massarotti, Julie Havas, Barbara Pistilli, Anne-Laure Martin, Alexandra Jacquet, Charles Coutant, Florence Coussy, Asma Dhaini Merimeche, Florence Lerebours, Olivier Tredan, Christelle Jouannaud, Olivier Rigal, Marion Fournier, Patrick Soulie, Maria Alice Franzoi, Lucia Del Mastro, Ann H. Partridge, Fabrice Andre, Ines Vaz-Luis, and Antonio Di Meglio more...
- Subjects
Cancer Research ,Oncology - Abstract
BACKGROUND: With an increased lifespan, survivorship has become a crucial component of breast cancer (BC) care. Among survivorship concerns, adequate contraception counseling is needed in premenopausal patients (pts) not seeking to become pregnant. However, very limited evidence exists on attitudes and factors influencing contraception use over time in premenopausal women with early BC. METHODS: CANTO is a multicenter, prospective cohort study of 12,012 pts with stage I-III BC (NCT01993498). This analysis included women aged ≤50 years with known premenopausal status at BC diagnosis. Contraception use and type were longitudinally evaluated at diagnosis, year-1 (T1) and 2 (T2) after diagnosis. Multivariable logistic regression models assessed associations between clinical, socio-economic, treatment, toxicity (CTCAE) and pts-reported outcome (PROs, EORTC QLQ-C30/BR23) variables, with contraception use after diagnosis. RESULTS: Among 2,900 pts included, mean age at diagnosis was 43.1 (SD 5.6) years, 96.0% of pts already had children at BC diagnosis, 70.8% and 80.0% received chemotherapy and endocrine therapy (ET), respectively. Among patients treated with ET, 80.2% received tamoxifen alone and 19.8% other therapies (either tamoxifen or an aromatase inhibitor or a combination) plus ovarian function suppression (OFS). Following diagnosis, 45.0% of pts at T1 and 65.7% at T2 reported consulting a gynecologist. At diagnosis, 54.2% of pts reported contraception use, with the majority (62.6%) using hormonal methods. Prevalence of contraception use significantly decreased at T1 and T2 (38.9% and 41.2%, respectively; ptrend Citation Format: Matteo Lambertini, Claudia Massarotti, Julie Havas, Barbara Pistilli, Anne-Laure Martin, Alexandra Jacquet, Charles Coutant, Florence Coussy, Asma Dhaini Merimeche, Florence Lerebours, Olivier Tredan, Christelle Jouannaud, Olivier Rigal, Marion Fournier, Patrick Soulie, Maria Alice Franzoi, Lucia Del Mastro, Ann H. Partridge, Fabrice Andre, Ines Vaz-Luis, Antonio Di Meglio. Attitudes and factors influencing contraception use over time in premenopausal women with early breast cancer in the prospective CANTO study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-11-20. more...
- Published
- 2022
- Full Text
- View/download PDF
16. Abstract GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial
- Author
-
Giampaolo Bianchini, Luca Malorni, Grazia Arpino, Alberto Zambelli, Fabio Puglisi, Lucia Del Mastro, Marco Colleoni, Filippo Montemurro, Giulia Bianchi, Ida Paris, Giacomo Allegrini, Marina Elena Cazzaniga, Michele Orditura, Claudio Zamagni, Stefano Tamberi, Daniela Castelletti, Matteo Benelli, Maurizio Callari, Angela Santoro, and Michelino De Laurentiis more...
- Subjects
Cancer Research ,Oncology - Abstract
Background: ctDNA analysis is emerging as an attractive non-invasive approach to characterize tumor biology, describe its evolution over time, and predict treatment benefit. Here, we assessed the prognostic and predictive role of baseline and dynamic ctDNA analysis in HR+/HER2- aBC patients (pts) treated with R+L. Methods: 287 postmenopausal pts were enrolled in the BioItaLEE trial (NCT03439046). Liquid biopsies were collected at baseline (D0; n=263), day 15 of cycle 1 (D15; n=238), day 1 of cycle 2 (C2D1; n=241) and at first imaging (FI, at approximately 12 weeks; n=206). ctDNA analysis was carried out using a 533-amplicon Custom AmpliSeq HD Panel, with amplicons covering the coding exons of 39 BC-related genes (limit of detection: 0.1%). Target mutations were defined as single-nucleotide variant (SNV) or Insertion/Deletion detected at D0. When multiple target mutations were detected, the one with the highest variant allele frequency (VAF) was considered. The association between pre-treatment and on-treatment ctDNA dynamics with progression-free survival (PFS) was assessed using Multivariate Cox models. VAF clearance was defined as 100% decrease in a target mutation. Results: Median follow-up was 26.9 months and median PFS was 23.39 (20.8-NE) months. At baseline, target mutations were detected in 113 pts (43.0%), whereas 150 pts were wild-type (wt). Mean (SD) pre-treatment VAF at D0 was 11.3% (14.4). The absence of a target mutation at D0 was associated with good prognosis (HR: 0.41, 95% CI: 0.27–0.61; p Citation Format: Giampaolo Bianchini, Luca Malorni, Grazia Arpino, Alberto Zambelli, Fabio Puglisi, Lucia Del Mastro, Marco Colleoni, Filippo Montemurro, Giulia Bianchi, Ida Paris, Giacomo Allegrini, Marina Elena Cazzaniga, Michele Orditura, Claudio Zamagni, Stefano Tamberi, Daniela Castelletti, Matteo Benelli, Maurizio Callari, Angela Santoro, Michelino De Laurentiis. Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr GS3-07. more...
- Published
- 2022
- Full Text
- View/download PDF
17. Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial
- Author
-
Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Robert S. Seitz, Tyler J. Nielsen, Marc Thill, Antonio Anton, Stefania Russo, Eva Maria Ciruelos, Brock L. Schweitzer, Douglas T. Ross, Barbara Galbardi, Richard Greil, Vladimir Semiglazov, Balázs Gyorffy, Marco Colleoni, Catherine Kelly, Gabriella Mariani, Lucia Del Mastro, Pinuccia Valagussa, Giuseppe Viale, Maurizio Callari, Luca Gianni, and Giampaolo Bianchini more...
- Subjects
Cancer Research ,Oncology - Abstract
Background A post-hoc of NeoTRIP trial showed that 27-gene IO score assessed on baseline samples is predictive of increased pathological complete response (pCR) with the addition of atezolizumab to carboplatin/nab-paclitaxel, whereas the LAR subtype has the lowest rate of pCR with and without atezolizumab (Bianchini G ESMO 2021). We evaluated 27-gene IO score and TNBC subtypes on biopsies collected during treatment, assessed biomarker dynamics, and studied the association with pCR. Methods In NeoTRIP, patients randomly received 8 cycles of nab-paclitaxel/carbo alone (CT) or with atezolizumab (CT/A). 258 patients were evaluable for pCR (Per-Protocol Population). We assessed IO score as binary and continuous variable, and the five 101-gene TNBC types (BL1, BL2, LAR, M, and MSL; Ring et al 2016) by RNA-seq on biopsies at baseline and day 1 of second treatment cycle (d1c2) (n: baseline 242/258, 94%; d2c2 161/258, 62%; paired 152/258, 59%). Forty-four paired samples were excluded due to lack of tumor cells at d1c2. PD-L1 (Ventana SP142) and sTILs data were available. We evaluated the association with pCR of biomarkers assessed at d1c2 and their dynamics from baseline. Results Frequency of TNBC types at d1c2 showed minor differences between arms (p = 0.055). TNBC type frequencies were 22.9% BL1, 11.4% BL2, 22.9% LAR, 21.4% M, and 21.4% MSL in the CT/A arm and 43.8% BL1, 6.2% BL2, 11.2% LAR, 21.2% M, and 17.5% MSL in the CT arm. Individual TNBC type changes from baseline to d1c2 were observed, but overall, it was not significant. Frequency of IO positive score at d1c2 was similar in CT and CT/A arm (p = 0.75). Only in CT/A, an increase from baseline to d1c2 was observed (30.9% to 49.3%, p = 0.04).Overall, TNBC types at d1c2 were predictive of pCR (p = 0.00002). Compared to BL1, LAR and M were associated with lower pCR rate in CT (OR = 0.09, 95% CI = 0.01-0.83, p = 0.034 for LAR; OR = 0.16, 95% CI = 0.04-0.66, p = 0.011 for M) and CT/A arm (OR = 0.05, 95% CI = 0.01-0.49, p = 0.010 for LAR; OR = 0.28, 95% CI = 0.06-1.28, p = 0.102). pCR rate in LAR was 11.1% and 6.2% in CT and CT/A arm, respectively. TNBC types were predictive of pCR independently of PD-L1 and sTILs.Continuous IO score at d1c2 was predictive of pCR in both CT/A (p = 0.004) and CT arms (p = 0.009). The binary IO score was significantly associated to higher pCR rate in CT/A arm only (OR = 5.42, 95% CI = 1.95-15.07, p = 0.001). A strong predictive value of the highest quartile of IO score compared to the lowest was observed in CT/A (OR = 14.73, 95% CI = 2.97-73.21, p = 0.001) and CT (OR = 4.38, 95% CI = 1.21-15.81, p = 0.024) arms. pCR rates for the highest and lowest quartiles were 72.2% vs 15.0% in CT/A and 65.2% vs 30.0% in CT arm. In CT/A binary IO score at d1c2 retained significance after adjustment for baseline PD-L1 and sTILs (p = 0.036).Combining baseline and d1c2 IO score, only d1c2 assessment was informative in CT arm. In CT/A arm, both biomarkers were informative, with assessment at d1c2 being more informative than baseline IO score when continuous scores were considered. Baseline binary IO score (OR = 25.0, 95% CI = 3.31-188.9, p = 0.002) and ΔIO score (d1c2-baseline) (OR = 11.3, 95% CI = 1.07-120.1, p = 0.044) retained significance. The combination of baseline and d1c2 binary IO score defined four groups with different likelihood of pCR: 73.7% vs 15.2% in positive/positive and negative/negative groups, respectively (OR = 15.68, 95% CI = 3.88-63.32, p = 0.0001). Conclusions Dynamic of IO score early on treatment was linked to likelihood of pCR independently of baseline biomarkers and may be an early surrogate of treatment benefit especially in atezolizumab arm. LAR and M are associated with lower pCR rate, suggesting that different therapeutic strategies may be beneficial. Combining baseline and on-treatment biomarkers can be more informative than baseline only of the complex tumor/immune co-evolution dynamic and of clinical outcome. Citation Format: Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Robert S. Seitz, Tyler J. Nielsen, Marc Thill, Antonio Anton, Stefania Russo, Eva Maria Ciruelos, Brock L. Schweitzer, Douglas T. Ross, Barbara Galbardi, Richard Greil, Vladimir Semiglazov, Balázs Gyorffy, Marco Colleoni, Catherine Kelly, Gabriella Mariani, Lucia Del Mastro, Pinuccia Valagussa, Giuseppe Viale, Maurizio Callari, Luca Gianni, Giampaolo Bianchini. Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-07-12. more...
- Published
- 2022
- Full Text
- View/download PDF
18. Abstract P3-09-03: Single nucletotide polymorphisms of aromatase gene (CYP19A1) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study
- Author
-
Benedetta Conte, Chiara Molinelli, Giancarlo Bisagni, Antonio Durando, Giovanni Sanna, Stefania Gori, Ornella Garrone, Stefano Tamberi, Sabino De Placido, Francesco Schettini, Antonio Pazzola, Riccardo Ponzone, Filippo Montemurro, Gianluigi Lunardi, Rosario Notaro, Anna Turletti, Claudia Bighin, Francesca Poggio, Giulia Buzzatti, Matteo Lambertini, Luca Boni, and Lucia Del Mastro more...
- Subjects
Cancer Research ,Oncology - Abstract
Background: Extending adjuvant endocrine treatment (ET) with aromatase inhibitors (AI) to 7-10 years decreases the risk of relapse in hormone receptor-positive (HR+) breast cancer (BC). However, such benefit comes at the price of higher incidence of skeletal and cardiovascular (CV) events. Biomarkers predicting such toxicities might help clinicians in tailoring adjuvant ET to patient’s needs. We conducted a prospective study to assess whether SNPs in the gene encoding for the aromatase enzyme (CYP19A1) affect the risk of skeletal and CV events in HR+ early BC patients enrolled in the GIM4 trial. Methods: The GIM4 trial randomized HR+ BC postmenopausal patients who had been already treated with 2-3 years of adjuvant tamoxifen to either 3-2 years or 5 years of adjuvant letrozole. Four SNPs of CYP19A1 were evaluated: rs10046, rs4646, rs479292 and rs727479. SNPs were genotyped through PCR on DNA obtained from patients’ peripheral blood samples. Skeletal and CV events were assessed from randomization in the GIM4 trial to last follow-up, disease recurrence or death. Skeletal events were defined as the onset of osteoporosis or bone fractures. CV events were defined as the onset of thrombosis, embolism, stroke, myocardial infarction, hearth failure, or arrythmia. Univariate and multivariate logistic regressions were performed to evaluate the association between SNPs and skeletal and CV events. Bonferroni correction for multiplicity was used for univariate SNPs association tests, with a corrected alpha of 0.012. Only associations with an alpha level Citation Format: Benedetta Conte, Chiara Molinelli, Giancarlo Bisagni, Antonio Durando, Giovanni Sanna, Stefania Gori, Ornella Garrone, Stefano Tamberi, Sabino De Placido, Francesco Schettini, Antonio Pazzola, Riccardo Ponzone, Filippo Montemurro, Gianluigi Lunardi, Rosario Notaro, Anna Turletti, Claudia Bighin, Francesca Poggio, Giulia Buzzatti, Matteo Lambertini, Luca Boni, Lucia Del Mastro. Single nucletotide polymorphisms of aromatase gene (CYP19A1) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-09-03. more...
- Published
- 2022
- Full Text
- View/download PDF
19. Abstract P2-13-42: Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial
- Author
-
Matteo Lambertini, Shona Fielding, Sibylle Loibl, Wolfgang Janni, Emma Clark, Maria Alice Franzoi, Debora Fumagalli, Carmela Caballero, Luca Arecco, Sharon Salomoni, Noam F Ponde, Francesca Poggio, Hee Jeong Kim, Cynthia Villarreal-Garza, Olivia Pagani, Shani Paluch-Shimon, Alberto Ballestrero, Lucia Del Mastro, Martine Piccart, Jose Bines, Ann H. Partridge, and Evandro de Azambuja more...
- Subjects
Cancer Research ,Oncology - Abstract
Background: The poor prognostic value of young age at diagnosis appears to vary according to breast cancer (BC) subtype, although this has been studied mainly in hormone receptor-positive (HR+) disease, with limited data in HER2-positive BC and short follow-up. Limited evidence exists on the benefit of anti-HER2 therapy in young women with BC. Considering that age has historically been a rationale for overtreatment, further research efforts to better investigate the prognostic and predictive value of age are needed. This exploratory analysis conducted within the APHINITY trial aimed to investigate the prognostic and predictive value of young age in patients with HER2-positive early BC treated with modern chemotherapy and concurrent anti-HER2 targeted treatment. Methods: APHINITY (NCT01358877) is an international, placebo-controlled, double-blind randomized phase III trial in patients with HER2-positive early BC investigating the benefit of adding pertuzumab to adjuvant chemotherapy plus trastuzumab. For the purpose of the present analysis, 40 years of age at enrolment was used as the cut-off to distinguish between young (≤40 years) and older (>40 years) cohorts. Invasive disease-free survival (IDFS) was the primary endpoint. IDFS irrespective of treatment arm and the benefit of adding pertuzumab were evaluated in all patients by comparing the young and older cohorts and then according to centrally-assessed hormone receptor status. Univariate and multivariable Cox proportional hazard models were used to assess the prognostic and predictive value of age on IDFS as a continuous and dichotomous variable (≤40 years and >40 years). A STEPP analysis was also conducted to illustrate possible treatment-effect heterogeneity based on age as a continuous factor. Results: Out of 4,804 patients in the ITT population, 768 (16.0%) were ≤40 years at enrollment. Patients in the young cohort were less overweight/obese (29.3% vs. 50.4%), underwent mastectomy more frequently (63.2% vs. 52.6%), had higher rates of node positive (66.4% vs. 61.8%) and HR+ (71.7% vs. 64.9%) BC as compared to those in the older cohort (all p Citation Format: Matteo Lambertini, Shona Fielding, Sibylle Loibl, Wolfgang Janni, Emma Clark, Maria Alice Franzoi, Debora Fumagalli, Carmela Caballero, Luca Arecco, Sharon Salomoni, Noam F Ponde, Francesca Poggio, Hee Jeong Kim, Cynthia Villarreal-Garza, Olivia Pagani, Shani Paluch-Shimon, Alberto Ballestrero, Lucia Del Mastro, Martine Piccart, Jose Bines, Ann H. Partridge, Evandro de Azambuja. Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-13-42. more...
- Published
- 2022
- Full Text
- View/download PDF
20. Supplementary Data from Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET)
- Author
-
Filippo de Braud, Luigi Mariani, Giancarlo Pruneri, Valentina Guarneri, Enrico Cortesi, Andrea Michelotti, Lucia Del Mastro, Giuseppe Curigliano, Filippo Montemurro, Agnese Losurdo, Daniele Generali, Alessandra Fabi, Rebecca Pedersini, Mariangela Ciccarese, Andrea Rocca, Grazia Arpino, Nicla La Verde, Fabio Puglisi, Lorenzo Gerratana, Salvatore Lo Vullo, Lorenzo Castagnoli, Arta Ajazi, Marika Cinausero, Debora Basile, Anna Moretti, Michela Palleschi, Amelia Vantaggiato, Giovanna Catania, Ottavia Bernocchi, Elisa Agostinetto, Andrea Milani, Dario Trapani, Emanuela Ferraro, Agnese Fabbri, Chiara Molinelli, Claudia De Angelis, Simone Scagnoli, Francesca Ligorio, Carmen G. Rea, Giovanni Randon, Antonio Marra, Gaia Griguolo, Carlo Alberto Giorgi, Luca Moscetti, Luca Lalli, Federico Nichetti, and Claudio Vernieri more...
- Abstract
Supplementary Tables and Figures
- Published
- 2023
- Full Text
- View/download PDF
21. Near-Field Diagnosis of an X-band Telemetry Antenna using Infrared Thermography
- Author
-
A. Laffont, S. Faure, M. Del Mastro, Q. Lamotte, J. Bhatker, M. Romier, and D. Prost
- Published
- 2023
- Full Text
- View/download PDF
22. Detecting preeclampsia with a multiple protein serum test: Assay and algorithm development
- Author
-
Amin R. Mazloom, Mohammad Abbasi, Steven Lockton, Sharat Singh, Richard Del Mastro, Christopher Robinson, Michael J Paglia, Philip Uren, Jenna Hendershot, Pankaj Oberoi, and Matthew Cooper
- Abstract
Background Preeclampsia is a common cause of maternal and neonatal mortality, and to date there is no definitive, diagnostic test available. We aimed to develop a test to detect preeclampsia using biomarkers representing different pathogenic pathways of disease. Methods A multi-stage development process was used to identify, prioritize, and assess performance of the biomarkers. Samples from symptomatic, asymptomatic, and subjects diagnosed with preeclampsia were screened to produce an algorithm with eight proteins and one clinical biomarker in order to report a binary output of “positive” or “negative”. Test performance was reported on a development cohort, and analytical validation was completed for the underlying protein assays. Results The algorithm resulted sensitivity of 90.6% (CI: 83.1%-95.0%), specificity of 78.4% (CI: 73.9%-82.4%), negative predictive value (NPV) of 96.9% (CI: 94.3%-98.4%), and positive predictive value (PPV) of 52.7% (CI: 45.1%-60.2%) for classification of presence or absence of preeclampsia. Conclusion A panel of biomarkers representing different physiological pathways in preeclampsia measured in serum of symptomatic women provides a sensitive binary classification of presence or absence of disease. more...
- Published
- 2023
- Full Text
- View/download PDF
23. Italian immigration to Australia 1920 to 1940 : the Sammarchese
- Author
-
Del Mastro, Patrick Michael.
- Abstract
This thesis was scanned from the print manuscript for digital preservation and is copyright the author. Researchers can access this thesis by asking their local university, institution or public library to make a request on their behalf. Monash staff and postgraduate students can use the link in the References field. more...
- Published
- 2023
- Full Text
- View/download PDF
24. 66P Outcome predictors for pembrolizumab alone or with chemotherapy in advanced non-small cell lung cancer (NSCLC)
- Author
-
L. Zullo, E. Cella, F. Paoloni, M. Gualtieri, G. Barletta, D. Favero, F. Parisi, C. Dellepiane, G. Rossi, E. Bennicelli, L. Zinoli, L. Cantini, F. Pecci, L. Del Mastro, R. Berardi, and C. Genova
- Subjects
Pulmonary and Respiratory Medicine ,Oncology - Published
- 2023
- Full Text
- View/download PDF
25. P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes
- Author
-
S. Johnston, M. Toi, J. O’Shaughnessy, P. Rastogi, M. Campone, P. Neven, C.S. Huang, J. Huober, G. Garnica Jaliffe, I. Cicin, S. Tolaney, M.P. Goetz, H. Rugo, E. Senkus, L. Testa, L. Del Mastro, C. Shimizu, R. Wei, A. Shahir, M. Munoz, B. San Antonio, V. Andre, N. Harbeck, and M. Martín more...
- Subjects
Surgery ,General Medicine - Published
- 2023
- Full Text
- View/download PDF
26. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis
- Author
-
Lucia Del Mastro, Marco Tagliamento, M.A. Franzoi, Piero Fregatti, Maria Grazia Razeti, Marcello Ceppi, Matteo Lambertini, Tommaso Ruelle, Marco Bruzzone, Paolo Pronzato, Claudia Massarotti, and Francesca Poggio more...
- Subjects
Cancer Research ,medicine.medical_specialty ,Hormone Replacement Therapy ,Breast Neoplasms ,Subgroup analysis ,Tibolone ,Placebo ,law.invention ,Breast cancer ,Cancer Survivors ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Survivors ,Randomized Controlled Trials as Topic ,business.industry ,Estrogen Replacement Therapy ,Hazard ratio ,medicine.disease ,Menopause ,Oncology ,Transgender hormone therapy ,Female ,Neoplasm Recurrence, Local ,business ,medicine.drug - Abstract
Symptoms of treatment-induced menopause negatively affect quality of life and adherence to endocrine therapy of breast cancer (BC) survivors. Nevertheless, the use of systemic hormone replacement therapy (HRT) to mitigate these symptoms may be associated with an increased risk of disease recurrence in these patients. This systematic review and meta-analysis aimed to assess the safety of systemic HRT on risk of disease recurrence in BC survivors. A systematic search of PubMed up to April 20, 2021 was conducted to identify randomized controlled trials (RCTs) that investigated the risk of disease recurrence with the use of HRT in BC survivors. A random-effect model was applied to calculate the risk of recurrence, reported as pooled hazard ratio (HR) with 95% confidence intervals (CI). A subgroup analysis was performed to estimate the risk of recurrence according to hormone receptor status. Four RCTs were included in the meta-analysis (n = 4050 patients). Overall, 2022 patients were randomized to receive HRT (estrogen/progestogen combination or tibolone) and 2023 to the control group with placebo or no HRT. HRT significantly increased the risk of BC recurrence compared to placebo (HR 1.46, 95% CI 1.12–1.91, p = 0.006). At the subgroup analysis, the risk of BC recurrence with the use of HRT was significantly increased in patients with hormone receptor-positive disease (HR 1.8, 95% CI 1.15–2.82, p = 0.010) but not in those with hormone receptor-negative tumors (HR 1.19, 95% CI 0.80–1.77, p = 0.390). Use of HRT was associated with a detrimental prognostic effect in BC survivors, particularly in those with hormone receptor-positive disease. Alternative interventions to mitigate menopause-related symptoms should be proposed. more...
- Published
- 2021
- Full Text
- View/download PDF
27. Study on the sociocultural profile of women working in a Brazilian nuclear area institution
- Author
-
Ana Gabryele Moreira dos Santos, Priscila Santos Rodrigues, Karoline Feitoza Suzart, and Nelida Del Mastro
- Subjects
General Agricultural and Biological Sciences - Abstract
RESUMO A representação feminina na tecnologia nuclear ainda é uma questão global em termos de igualdade de gênero e ainda há um baixo número de mulheres nessa área. O objetivo deste trabalho foi avaliar a participação feminina em um instituto de pesquisa nuclear (instituição vinculada ao estado de São Paulo e ao governo federal brasileiro), verificar como estão distribuídas as mulheres que trabalham nessa unidade, qual a sua área de atuação e posição nos níveis de carreira. A pesquisa foi realizada por meio de um formulário online, respondido voluntariamente, que continha perguntas para traçar o perfil dessas mulheres, bem como para entender como se mostrava a presença feminina no ambiente de trabalho. Os resultados mostraram que o perfil majoritário é de mulheres brancas, pós-graduandos com até 41 anos, naturais da região Sudeste, predominantemente paulistas, que são/foram orientadas por homens, que não conhecem a associação Women in Nuclear e um percentual considerável desconhece a pesquisadora pioneira em sua área de atuação, evidenciando a falta de informação sobre a representação feminina neste campo. Percebe-se que no Brasil, a construção de uma representação igualitária na área nuclear está em andamento e ainda tem um longo caminho a percorrer, mostrando que pesquisas como o presente levantamento e divulgação de eventos sobre mulheres é algo que precisa ser feito com mais frequência para enfatizar a importância da presença feminina nas ciências. Keywords: nuclear technology, women, researchers, gender equity, female representation. more...
- Published
- 2022
- Full Text
- View/download PDF
28. La formazione permanente e l’autobiografia musicale. Lifelong learning and musical autobiography
- Author
-
Strollo M. R., Del Mastro M. C., El Haj M., Strollo, M. R., Del Mastro, M. C., and El Haj, M.
- Published
- 2022
29. Nuovi Scribi Ercolanesi
- Author
-
Gianluca Del Mastro, Marzia D'Angelo, DEL MASTRO, Gianluca, and D'Angelo, Marzia
- Subjects
Herculaneum, Papyri, Paleography, Handwritings - Published
- 2022
30. EMOZIONI E META-EMOZIONI NEI CONTESTI FOR-MATIVI
- Author
-
Del Mastro M. C., Strollo M. R., Del Mastro, M. C., and Strollo, M. R.
- Published
- 2022
31. First Surgical National Consensus Conference of the Italian Breast Surgeons association (ANISC) on breast cancer management in neoadjuvant setting: Results and summary
- Author
-
Federica Buzzacchino, Emiel J. Th. Rutgers, Mauro Minelli, Federico Frusone, Mario Taffurelli, Alessandro De Luca, Virgilio Sacchini, Lucio Fortunato, Francesco Caruso, Maria Ida Amabile, and Lucia Del Mastro more...
- Subjects
medicine.medical_specialty ,Receptor, ErbB-2 ,Breast surgery ,medicine.medical_treatment ,Sentinel lymph node ,Antineoplastic Agents ,Triple Negative Breast Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,medicine ,Humans ,030212 general & internal medicine ,Lymph node ,Mastectomy ,Neoadjuvant therapy ,Neoplasm Staging ,Clinical Trials as Topic ,Breast surgeons ,business.industry ,Patient Selection ,General surgery ,Axillary Lymph Node Dissection ,Margins of Excision ,General Medicine ,medicine.disease ,Neoadjuvant Therapy ,Tumor Burden ,medicine.anatomical_structure ,Italy ,Oncology ,Neoplasm Micrometastasis ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Lymph Node Excision ,Female ,Surgery ,Neoplasm Grading ,business - Abstract
Rationale On October 15th, 2020, the first Surgical National Consensus Conference on neoadjuvant chemotherapy (NACT) was promoted by the Italian Association of Breast Surgeons (ANISC). Method The Consensus Conference was entirely held online due to anti-Covid-19 restrictions and after an introductory four lectures held by national and international experts in the field, a total of nine questions were presented and a digital “real-time” voting system was obtained. A consensus was reached if 75% or more of all panelists agreed on a given question. Results A total of 202 physicians, from 76 different Italian Breast Centers homogeneously distributed throughout the Italian country, participated to the Conference. Most participants were surgeons (75%). Consensus was reached for seven out of the nine considered topics, including management of margins and lymph nodes at surgery, and there was good correspondence between the 32 “Expert Panelists” and the “Participants” to the Conference. Consensus was not achieved regarding the indications to NACT for high-grade luminal-like breast tumors, and the need to perform an axillary lymph node dissection in case of micrometastases in the sentinel lymph node after NACT. Conclusions NACT is a topic of major interest among surgeons, and there is need to develop shared guidelines. While a Consensus was obtained for most issues presented at this Conference, controversies still exist regarding indications to NACT in luminal B-like tumors and management of lymph node micrometastases. There is need for clinical studies and analysis of large databases to improve our knowledge on this subject. more...
- Published
- 2021
- Full Text
- View/download PDF
32. Abstract PD5-07: Safety of assisted reproductive technologies before and after anticancer treatments in young women with breast cancer: A systematic review and meta-analysis
- Author
-
Luca Arecco, Eva Blondeaux, Marco Bruzzone, Marcello Ceppi, Maria Maddalena Latocca, Andrea Boutros, Camilla Marrocco, Maria Grazia Razeti, Maurizio Cosso, Stefano Spinaci, Margherita Condorelli, Claudia Massarotti, Lucia Del Mastro, Isabelle Demeestere, and Matteo Lambertini more...
- Subjects
Cancer Research ,Oncology - Abstract
Background: Controlled ovarian stimulation (COS) for oocyte/embryo cryopreservation before starting chemotherapy is standard of care for young women with breast cancer wishing to preserve fertility. However, some oncologists remain concerned on the safety of COS, particularly in patients with hormone-sensitive tumors. Moreover, limited evidence exists on the safety of assisted reproductive technologies (ART) in breast cancer survivors after completion of anticancer treatments. Material and methods: A systematic literature review with no date restriction up to June 30, 2021 was conducted to identify studies reporting results of oncological outcomes in breast cancer patients and survivors who underwent COS or other ART compared to patients and survivors who did not access these techniques. From each included study, recurrence ratio, event-free survival (EFS) and mortality rate were extracted. Pooled relative risks (RRs) and hazard ratios (HRs) with 95% confidence intervals (CI) were calculated using the random effects models. Results: Out of 15 included studies (n=4,643), 11 reported outcomes of patients who underwent COS for fertility preservation before starting chemotherapy, and 4 of survivors who underwent ART following anticancer treatment completion. Compared to women who did not receive fertility preservation at diagnosis (n=2,386), those who underwent COS (n=1,594) had reduced risk of recurrence (RR 0.58, 95% CI 0.46-0.73) or mortality (RR 0.54, 95% CI 0.38-0.76). No detrimental effect of COS on EFS was observed (HR 0.76, 95% CI 0.55-1.06). A similar trend of better outcomes in terms of EFS was observed in women with hormone-receptor positive disease who underwent COS (HR 0.36, 95% CI 0.20-0.65).Compared to women not exposed to ART following completion of anticancer treatments (n=540), those exposed to ART (n=123) showed a tendency for better outcomes in terms of recurrence ratio (RR 0.34, 95% CI 0.17-0.70) and EFS (HR 0.43, 95% CI 0.17-1.11). Conclusions: Despite including mostly retrospective studies, this meta-analysis suggests that accessing COS at diagnosis, also in hormone receptor-positive disease, or ART following treatment completion is not associated with detrimental prognostic effect in young women with breast cancer. These results are important to reassure patients and oncologists on the safety of these procedures to increase the chances of future conception. Citation Format: Luca Arecco, Eva Blondeaux, Marco Bruzzone, Marcello Ceppi, Maria Maddalena Latocca, Andrea Boutros, Camilla Marrocco, Maria Grazia Razeti, Maurizio Cosso, Stefano Spinaci, Margherita Condorelli, Claudia Massarotti, Lucia Del Mastro, Isabelle Demeestere, Matteo Lambertini. Safety of assisted reproductive technologies before and after anticancer treatments in young women with breast cancer: A systematic review and meta-analysis [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD5-07. more...
- Published
- 2022
- Full Text
- View/download PDF
33. Anclas líticas en el País Vasco: Catálogo de anclas líticas recuperadas en la costa guipuzcoana
- Author
-
Maria Intxaustegi Molina and Marta Del Mastro Ochoa
- Published
- 2022
- Full Text
- View/download PDF
34. Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
- Author
-
Mariarosaria Saponaro, Luigi Annunziata, Antonella Turla, Ilaria Viganò, Michele De Laurentiis, Mario Giuliano, Lucia Del Mastro, Filippo Montemurro, Fabio Puglisi, Carmine De Angelis, Giuseppe Buono, Francesco Schettini, and Grazia Arpino more...
- Subjects
Antineoplastic Agents, Hormonal ,Breast Neoplasms ,Hormone receptors ,Catalysis ,Càncer de mama ,Inorganic Chemistry ,Breast cancer ,Adjuvants, Immunologic ,late recurrence ,Humans ,Physical and Theoretical Chemistry ,Side effects ,Molecular Biology ,Hormone therapy ,Spectroscopy ,Efectes secundaris ,Adjuvants, Pharmaceutic ,Adjuvant treatment of cancer ,clinical score ,extended endocrine therapy ,genomic assays ,hormone receptor-positive breast cancer ,Receptors d'hormones ,Organic Chemistry ,General Medicine ,Genomics ,Computer Science Applications ,Genòmica ,Tamoxifen ,Chemotherapy, Adjuvant ,Female ,Neoplasm Recurrence, Local ,Hormonoteràpia ,Tractament adjuvant del càncer - Abstract
In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice. more...
- Published
- 2022
35. Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group
- Author
-
S.P. Gampenrieder, V. Dezentjé, M. Lambertini, A. de Nonneville, M. Marhold, F. Le Du, A. Cortés Salgado, D. Alpuim Costa, M. Vaz Batista, N. Chic Ruché, C. Tinchon, A. Petzer, E. Blondeaux, L. Del Mastro, G. Targato, F. Bertucci, A. Gonçalves, F. Viret, R. Bartsch, C. Mannsbart, A. Deleuze, L. Robert, C. Saavedra Serrano, M. Gion Cortés, M. Sampaio-Alves, M. Vitorino, L. Pecen, C. Singer, N. Harbeck, G. Rinnerthaler, R. Greil, Marija Balic, Sonja Heibl, August Felix Zabernigg, Daniel Egle, Margit Sandholzer, Florian Roitner, Johannes Andel, Petra Pichler, Christopher Hager, Michael Knauer, Michael Hubalek, Claudia Bighin, Michelino De Laurentiis, Sabino De Placido, Fabio Puglisi, Luca Boni, Amelie de Gregorio, Tom Degenhardt, Luigi Formisano, Karin Beelen, Timothy Robinson, Amanda Fitzpatrick, Veronique Dieras, Volkmar Muller, Alessandra Gennari, Sabine Linn, Sofia Braga, Javier Cortes, Carlo Palmieri, and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) more...
- Subjects
Cancer Research ,real-world data ,SDG 3 - Good Health and Well-being ,Oncology ,Receptor, ErbB-2 ,Receptor ErbB-2 ,triple-negative breast cancer ,Neoplasias de Mama Triplo Negativas ,OS ,Triple Negative Breast Neoplasms ,HER2-low ,prognosis ,metastatic - Abstract
Funding Information: This project was initiated at the Endeavour Breast Project coordinated by Daiichi Sankyo (special thanks to Christian Opitz and Britta Mazur from Daiichi Sankyo). We thank all participants and the steering committee members of the Endeavour Breast Meeting who are not listed as co-authors ( Supplementary Table S4 , available at https://doi.org/10.1016/j.esmoop.2022.100747 ). The authors gratefully acknowledge the support from the AGMT office (particularly Mag. Katrin Dorfinger, Mag. Alexandra Keuschnig, Sebastian Schütz, and Dr. Daniela Wolkersdorfer) and all trial coordinators at the contributing centers. Publisher Copyright: © 2022 The Authors Background: Triple-negative breast cancer (TNBC) is associated with poor prognosis, and new treatment options are urgently needed. About 34%-39% of primary TNBCs show a low expression of human epidermal growth factor receptor 2 (HER2-low), which is a target for new anti-HER2 drugs. However, little is known about the frequency and the prognostic value of HER2-low in metastatic TNBC. Patients and methods: We retrospectively included patients with TNBC from five European countries for this international, multicenter analysis. Triple-negativity had to be shown in a metastatic site or in the primary breast tumor diagnosed simultaneously or within 3 years before metastatic disease. HER2-low was defined as immunohistochemically (IHC) 1+ or 2+ without ERBB2 gene amplification. Survival probabilities were calculated by the Kaplan–Meier method, and multivariable hazard ratios (HRs) were estimated by Cox regression models. Results: In total, 691 patients, diagnosed between January 2006 and February 2021, were assessable. The incidence of HER2-low was 32.0% [95% confidence interval (CI) 28.5% to 35.5%], with similar proportions in metastases (n = 265; 29.8%) and primary tumors (n = 425; 33.4%; P = 0.324). The median overall survival (OS) in HER2-low and HER2-0 TNBC was 18.6 and 16.1 months, respectively (HR 1.00; 95% CI 0.83-1.19; P = 0.969). Similarly, in multivariable analysis, HER2-low had no significant impact on OS (HR 0.95; 95% CI 0.79-1.13; P = 0.545). No difference in prognosis was observed between HER2 IHC 0/1+ and IHC 2+ tumors (HR 0.89; 95% CI 0.69-1.17; P = 0.414). Conclusions: In this large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%. Neither in univariable nor in multivariable analysis HER2-low showed any influence on OS. publishersversion published more...
- Published
- 2022
36. PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology
- Author
-
Federica Miglietta, Michela Cinquini, Maria Vittoria Dieci, Laura Cortesi, Carmen Criscitiello, Filippo Montemurro, Lucia Del Mastro, Alberto Zambelli, Laura Biganzoli, Alessia Levaggi, Chiara Delle Piane, Caterina Marchiò, Massimo Calabrese, Lucio Fortunato, Pierfrancesco Franco, Bruno Meduri, Veronica Andrea Fittipaldo, and Stefania Gori more...
- Subjects
Breast cancer ,PARP-Inhibitors ,GRADE methodology ,BRCA germline mutations ,HER2-negative ,Surgery ,General Medicine - Abstract
Approximately 5-10% of unselected breast cancer (BC) patients retain a hereditary predisposition related to a germline mutation in BRCA1/2 genes. The poly-ADP ribose polymerase (PARP)-inhibitors olaparib and talazoparib have been granted marketing authorization by both FDA and EMA for adults with BRCA1/2 germline mutations and HER2-negative (HER2-) advanced BC based on the results from the phase III OlympiAd and EMBRACA trials.The panel of the Italian Association of Medical Oncology (AIOM) Clinical Practice Guidelines on Breast Cancer addressed two critical clinical questions, adopting the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach and the Evidence to Decision framework (EtD), to develop recommendations on the use of PARP-inhibitors, with respect to single-agent chemotherapy, in patients with BRCA-related triple-negative (clinical question 1) and hormone receptor-positive (HR+)/HER2- (clinical question 2) advanced BC.Two studies were eligible (OlympiAd and EMBRACA). For both clinical questions, the Panel judged the benefit/harm balance probably in favor of the intervention, given the favorable impact in terms of PFS, ORR, and QoL at an acceptable cost in terms of toxicity; the overall certainty of the evidence was low. The panel's final recommendations were conditional in favor of PARP-inhibitors over single-agent chemotherapy in both HR+/HER2-and triple-negative BC. Finally, the Panel identified and discussed areas of uncertainty calling for further exploration.The Panel of AIOM BC Clinical Practice Guideline provided clinical recommendations on the use of PARP-inhibitors, with respect to single-agent chemotherapy, in patients with BRCA-related HER2-advanced BC by adopting the GRADE methodology. more...
- Published
- 2022
37. Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
- Author
-
Alessandra Fabi, Giuseppe Buono, Emilio Bria, Giampaolo Bianchini, Giuseppe Curigliano, Michelino De Laurentiis, Sabino De Placido, Lucia Del Mastro, Valentina Guarneri, Daniele Generali, Lorenzo Livi, Vito Lorusso, Filippo Montemurro, Fabio Puglisi, Paolo Vigneri, Alberto Zambelli, and Grazia Arpino more...
- Subjects
Cancer Research ,CDK4/6i ,consensus ,Delphi survey ,metastatic HR+/HER2-breast cancer ,oncology ,Oncology - Abstract
The treatment of HR+/HER2- metastatic breast cancer with cyclin-dependent kinases 4 and 6 inhibitors combined with endocrine therapy has recently emerged as the most relevant therapeutic strategy. However, in routine clinical practice, the best therapeutic approach in patients with comorbidities at early relapsing or ab initio metastatic disease, PI3KCA mutation, is still debated among oncologists. Given these areas of uncertainty, we conducted a Delphi survey to describe and confront the level of agreement or disagreement between clinicians working in referral vs local spoke oncological hospitals and summarize a consensus on these debated topics. In total, 56 items were drafted using the Nominal Group Technique and used for the Delphi Survey. A total of 46 clinicians participated in the survey. Overall, the consensus threshold among all participants was reached in 46/56 items (82%), and Delphi Survey results showed a high level of consensus. For the 10 items (18%) that did not reach the consensus threshold, possible explanations considering differences in clinical practice and recent findings from literature are provided in the Discussion. Outcomes from the present survey may help guide treatment in multiple comorbidities, early recurring and ab initio metastatic disease, and PI3KCA mutation, where evidence from randomized trials and level 1 evidence is currently missing. more...
- Published
- 2022
- Full Text
- View/download PDF
38. Overall survival benefit in clinically relevant subgroups for CDK4/6 inhibitors combined with endocrine therapy in metastatic breast cancer: a meta-analysis
- Author
-
Schettini, Francesco, Giudici, Fabiola, Giuliano, Mario, Jerusalem, Guy, Cristofanilli, Massimo, Prat, Aleix, De Placido, Sabino, De Placido, Pietro, Llombart, Antonio, Dejan, Juric, Conte, Pierfranco, Arpino, Grazia, Venturini, Sergio, Del Mastro, Lucia, Puglisi, Fabio, De Laurentiis, Michelino, Di Leo, Angelo, and Generali, Daniele more...
- Subjects
skin and connective tissue diseases ,neoplasms - Abstract
Meta-analysis of the overall survival effect of CDK4/6 inhibitors + endocrine therapy combinations in prespecified clinically relevant subgroups of HR+ HER2- metastatic breast cancer
- Published
- 2022
- Full Text
- View/download PDF
39. Efficacy of endocrine- versus chemotherapy-based treatments in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer: a Network Meta-Analysis
- Author
-
Giuliano, Mario, Schettini, Francesco, Rognoni, Carla, Milani, Manuela, Jerusalem, Guy, Bachelot, Thomas, De Laurentiis, Michelino, Thomas, Guglielmo, De Placido, Pietro, Arpino, Grazia, De Placido, Sabino, Cristofanilli, Massimo, Giordano, Antonio, Puglisi, Fabio, Pistilli, Barbara, Prat, Aleix, Del Mastro, Lucia, Venturini, Sergio, and Generali, Daniele more...
- Abstract
Background: Despite international guidelines support the administration of hormone therapies (HT) ± targeted agents (TA) in postmenopausal hormone receptor positive (HR+ve), human epidermal growth factor receptor 2 negative (HER2-ve) metastatic breast cancer (mBC) [1-3], upfront use of chemotherapy (CT) is still common, even in the absence of life-threatening visceral disease [4-7]. This might be partly due to the lack of direct comparisons among HT and CT regimens. Therefore, in order to compare efficacy and activity of 1st/2nd line CT and HT-based strategies, we planned to perform a network meta-analysis (NMA) using the only methodology capable to compare different treatments that were not investigated head-to-head in randomized controlled trials (RCTs) [8,9]. Methods: We plan a systematic literature search to select all available phase II-III RCT published between January 2000 and December 2017, which evaluate CT or HT ± TA, as 1st and/or 2nd line treatments for postmenopausal women with HR+/HER2-mBC. Primary endpoint: progression-free survival (PFS)/time to tumor progression (TTP). Secondary endpoint: overall response rate (ORR). A Bayesian NMA will be generated to compare posterior median hazard ratios (HR) for PFS and odds ratios (OR) for ORR [8-16]. An endocrine standard first line treatment will be chosen as the HT common comparator for the overall analyses, among the most frequent treatments in the dataset. The combination of palbociclib (palbo) + letrozole (let) will be chosen as the HT + TA common comparator being, among the new 1st line standard of care, the first to be approved worldwide. References Cardoso F, Costa A, Senkus E et al., Ann Oncol 2017; 28 (1):16–33. NCCN clinical practice guidelines in Oncology – Breast Cancer 2018. Available on https://www.nccn.org/professionals Rugo HS, Rumble RB, Macrae E et al., J Clin Oncol 2016; 34(25):3069-3103. Andrè F, Neven P, Marinsek N, et al., Curr Med Res Opin 2014; 30:1007-1016. Bonotto M, Gerratana L, Di Maio M et al, The Breast 2017; 31:114-120. Cazzaniga M, Mustacchi G, Giordano M, et al. Ann Oncol 2017; 28(suppl_5): mdx365.022. Lobbezoo DJA, van Kampen RJW, Voogd AC et al., Ann Oncol 2016; 27: 256–262. Hoaglin DC, Hawkins N, Jansen JP et al., Value Health 2011; 14:429–437. Jansen JP, Fleurence R, Devine B et al., Value Health 2011; 14:417–428. Dias S, Welton NJ, Sutton AJ et al., Technical support document, NICE DSU, 2011. Available from http://www.nicedsu.org.uk. Gelman A, Carlin JB, Stern HS et al. Bayesian Data Analysis. 3rd edition: CRC Press, Boca Raton, Florida, USA, 2014. Jansen JP, BMC Medical Research Methodology 2011; 11: 1–14. Guyot P, Ades AE, Ouwens MJNM et al., BMC Medical Research Methodology 2012; 12:9. Ouwens MJNM, Philips Z, Jansen JP, Research Synthesis Methods 2010; 1:258–271. Parmar MKB, Torri V, Stewart L, Statistics in Medicine 1998; 17:2815–2834. Lunn DJ, Thomas A, Best N et al., Statistics and Computing 2000; 10:325–337. more...
- Published
- 2022
- Full Text
- View/download PDF
40. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial
- Author
-
Lucia Del Mastro, Francesca Poggio, Eva Blondeaux, Sabino De Placido, Mario Giuliano, Valeria Forestieri, Michelino De Laurentiis, Adriano Gravina, Giancarlo Bisagni, Anita Rimanti, Anna Turletti, Cecilia Nisticò, Angela Vaccaro, Francesco Cognetti, Alessandra Fabi, Simona Gasparro, Ornella Garrone, Maria Grazia Alicicco, Ylenia Urracci, Mauro Mansutti, Paola Poletti, Pierpaolo Correale, Claudia Bighin, Fabio Puglisi, Filippo Montemurro, Giuseppe Colantuoni, Matteo Lambertini, Luca Boni, M Venturini, A Abate, S Pastorino, G Canavese, C Vecchio, M Guenzi, M Lambertini, A Levaggi, S Giraudi, V Accortanzo, C.A. Floris, E Aitini, G Fornari, S Miraglia, G Buonfanti, M.C. Cherchi, F Petrelli, A Vaccaro, E Magnolfi, A Contu, R Labianca, A Parisi, C Basurto, F Cappuzzo, M Merlano, S Russo, M Mansutti, E Poletto, M Nardi, D Grasso, A Fontana, L Isa, M Comandè, L Cavanna, S Iacobelli, S Milani, G Mustacchi, S Venturini, A.F. Scinto, M.G. Sarobba, P Pugliese, A Bernardo, I Pavese, M Coccaro, B Massidda, M.T. Ionta, A Nuzzo, L Laudadio, V Chiantera, R Dottori, M Barduagni, F Castiglione, F Ciardiello, V Tinessa, A Ficorella, L Moscetti, I Vallini, G Giardina, R Silva, M Montedoro, E Seles, F Morano, G Cruciani, V Adamo, A Pancotti, V Palmisani, A Ruggeri, E Cammilluzzi, F Carrozza, M D'Aprile, M Brunetti, P Gallotti, E Chiesa, F Testore, A D'Arco, A Ferro, A Jirillo, M Pezzoli, G Scambia, C Iacono, P Masullo, G Tomasello, G Gandini, A Zoboli, C Bottero, M Cazzaniga, G Genua, S Palazzo, M D'Amico, and D Perrone more...
- Subjects
Oncology ,Paclitaxel ,Chemotherapy, Adjuvant ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Breast Neoplasms ,Fluorouracil ,Cyclophosphamide ,Epirubicin - Abstract
Previous analyses of the GIM (Gruppo Italiano Mammella) 2 study showed that addition of fluorouracil to epirubicin, cyclophosphamide, and paclitaxel in patients with node-positive early breast cancer does not improve outcome, whereas dose-dense chemotherapy induces a significant improvement in both disease-free survival and overall survival as compared with a standard schedule. Here, we present long-term results of the study.In this 2 × 2 factorial, open-label, randomised, phase 3 trial, we enrolled patients aged 18-70 years with operable, node-positive, breast cancer with Eastern Cooperative Oncology Group performance status of 0-1 from 81 hospitals in Italy. Eligible patients were randomly allocated (1:1:1:1) to one of the four following study groups: four cycles of standard-interval intravenous EC (epirubicin 90 mg/mBetween April 24, 2003, and July 3, 2006, 2091 patients were randomly assigned to treatment: 545 to q3EC-P, 544 to q3FEC-P, 502 to q2EC-P, and 500 to q2FEC-P. 88 patients were enrolled in centres providing only standard interval schedule and were assigned only to q3FEC-P and q3EC-P; thus, 2091 patients were included in the intention-to-treat analysis for the comparison of EC-P (1047 patients) versus FEC-P (1044 patients) and 2003 patients were included in the intention-to-treat analysis for the comparison of dose-dense (1002 patients) versus standard interval analysis (1001 patients). After a median follow-up of 15·1 years (IQR 8·4-16·3), median disease-free survival was not significantly different between FEC-P and EC-P groups (17·09 years [95% CI 15·51-not reached] vs not reached [17·54-not reached]; unadjusted hazard ratio 1·12 [95% CI 0·98-1·29]; log-rank p=0·11). Median disease-free survival was significantly higher in the dose-dense interval group than the standard-interval group (not reached [95% CI 17·45-not reached] vs 16·52 [14·24-17·54]; 0·77 [95% CI 0·67-0·89]; p=0·0004). The most common grade 3-4 adverse events were neutropenia (200 [37%] of 536 patients in the q3EC-P group vs 257 [48%] of 533 in the q3FEC-P group vs 50 [10%] of 496 q2EC-P vs 97 [20%] of 492) and alopecia (238 [44%] vs 249 [47%] vs 228 [46%] vs 235 [48%]). During extended follow-up, no further grade 3-4 adverse events or deaths related to toxic-effects were reported. Treatment-related serious adverse events were reported in nine (2%) patients in the q3EC-P group, seven (1%) in the q3FEC-P group, nine (2%) in the q2EC-P group, and nine (2%) in the q2FEC-P group. No treatment-related deaths occurred.Updated results from the GIM2 study support that optimal adjuvant chemotherapy for patients with high-risk early breast cancer should not include fluorouracil and should use a dose-dense schedule.Bristol-Myers Squibb, Pharmacia, Dompè Biotec Italy, Italian Ministry of Health, Fondazione Italiana per la Ricerca sul Cancro, and Alliance Against Cancer. more...
- Published
- 2022
41. Experience with a nurse-driven genetic counseling pathway of Italian women with uninformative BRCA test result
- Author
-
Eva Blondeaux, Matteo Lambertini, Giulia Buzzatti, Carla Bruzzone, Marina Baraga, Roberta Pisani, Lucia Del Mastro, Paolo Pronzato, Liliana Varesco, and Luigina Bonelli
- Subjects
Genetics (clinical) - Abstract
Several models of genetic counseling have been proposed to tackle the increasing volume of individuals requiring access to BRCA testing. Few data are available on patient experience and retention of information with nurse-driven genetic counseling. We evaluated the experience and retention of information in women with an uninformative BRCA test result and who were not considered at high risk due to their personal/family history of cancer who underwent geneticist-supervised nurse-driven genetic counseling and who received their test result by phone. Women who received an uninformative BRCA test result between May 2017 and September 2019 were administered a questionnaire exploring experience with genetic counseling and retention of information provided. Of 366 eligible women, 299 (273 breast cancer patients and 26 women without breast cancer) completed the interview. Overall, 280 women (93.6%) positively valued their experience with genetic counseling and 287 (96.0%) considered it helpful with 57.5% of them feeling reassured for themselves and their family. Information on the clinical implications of the test result was correctly retained and women acted accordingly. Overall, 252 women (87.8%) accurately reported their test result as normal/negative. Only 67 (22.4%) recognized that despite a normal BRCA test result, a low probability of a hereditary syndrome remains. Most women showed a poor ability to estimate cancer risk in BRCA mutation carriers and in the general population. Geneticist-supervised nurse-driven genetic counseling process for women with uninformative BRCA test result is associated with a positive patient experience and an adequate retention of information concerning the management of their personal and familial cancer risk. The design and implementation of nurse-driven genetic counseling models may contribute to efficient and timely access to BRCA genetic testing. more...
- Published
- 2022
42. A multi-user virtual reality experience for space missions
- Author
-
A. Del Mastro, Federico Monaco, and Y. Benyoucef
- Subjects
020301 aerospace & aeronautics ,Situation awareness ,Computer science ,Aerospace Engineering ,02 engineering and technology ,Mars Exploration Program ,Virtual reality ,Multi-user ,01 natural sciences ,Space exploration ,Task (project management) ,0203 mechanical engineering ,Human–computer interaction ,0103 physical sciences ,Command and control ,Safety, Risk, Reliability and Quality ,010303 astronomy & astrophysics ,Space environment - Abstract
Simulations in augmented (AR) and virtual reality (VR) environments are increasingly part of space programs studying human-crewed missions to Moon and Mars. The goal of these simulation programs is to both train crews and study human behaviour in extreme conditions environments. A virtual multiuser experience (VMUE) consists of the virtual simulation of knowledge shared by at least two users interacting with each other and with the surrounding critical environment. In the space sector, VMUE is a relatively low cost means of simulating the concurrent activities of astronauts interacting with a simulated space environment that can be rolled out right from the start of the project. Applications include training in exploration, maintenance and inspection, ground/space station communication, command and control task execution on robotic systems, and most importantly, crisis resource management (CRM) with situational awareness training in safety analysis and risk prevention. The VR multiuser experience can also be combined with AR devices to obtain a wide range of simulation capabilities and collaborative operations in a hybrid environment. Given the critical importance of multiuser experience in VR and AR, this paper aims to offer a short review of the Mars Planet Research Group's activities, namely: High level-of-likelihood reconstruction of entire regions of Mars/Moon to be used in the VR environment; Development and combination of the two VR treadmills - MOTIVITY and MOTIGRAVITY - for a series of scientific operations and simulations, including physical and medical rehabilitation and education. more...
- Published
- 2021
- Full Text
- View/download PDF
43. Sustainable Development: Understanding The Least Resource Base
- Author
-
Josef Strobl, Vladimir S. Tikunov, Federico Monaсo, Antonio Del Mastro, and Eugene Eremchenko
- Subjects
Resource (biology) ,media_common.quotation_subject ,Geography, Planning and Development ,Context (language use) ,Environmental Science (miscellaneous) ,03 medical and health sciences ,habitats ,Human settlement ,0502 economics and business ,resource base ,050207 economics ,Environmental planning ,030304 developmental biology ,media_common ,Sustainable development ,Geography (General) ,0303 health sciences ,sustainable development ,Civilization ,05 social sciences ,Isolationism ,Geography ,Sustainability ,G1-922 ,isolationism ,Globalism - Abstract
In the paper, the least resource base required to ensure isolated human habitat sustainability over a historically long period of time is discussed. Territory and energy are proposed as such basic resources. The analysis of isolated societies of Tasmania, the Chatham Islands, and North Sentinel Island concludes that habitat can exist long and sustainably in a local area of at least 30 square kilometres in a mode of inherent safety, without the use of artificial technologies. This conclusion demonstrates the possibility of sustainable development of human civilization as a sum of local communities in the context of the isolationism paradigm, an alternative to globalism’s currently dominant concept. The significance of identifying the least resource base of sustainable development of isolated communities in the context of the establishment of scientific bases and settlements in remote areas of the globe, on the Moon and other planets of the solar system, and developing strategies to combat pandemics such as COVID-19, is highlighted. more...
- Published
- 2021
- Full Text
- View/download PDF
44. Corrigendum to 'Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review' [Cancer Treatm. Rev. 114 (2023) 102511]
- Author
-
F. Miglietta, A. Fabi, D. Generali, M.V. Dieci, G. Arpino, G. Bianchini, S. Cinieri, P.F. Conte, G. Curigliano, Michelino De Laurentiis, L. Del Mastro, S. De Placido, A. Gennari, F. Puglisi, A. Zambelli, F. Perrone, and V. Guarneri more...
- Subjects
Oncology ,Radiology, Nuclear Medicine and imaging ,General Medicine - Published
- 2023
- Full Text
- View/download PDF
45. Booster Dose of SARS-CoV-2 mRNA Vaccine in Kidney Transplanted Patients Induces Wuhan-Hu-1 Specific Neutralizing Antibodies and T Cell Activation but Lower Response against Omicron Variant
- Author
-
Andrea Del Mastro, Stefania Picascia, Luciana D’Apice, Maria Trovato, Pasquale Barba, Immacolata Di Biase, Sebastiano Di Biase, Marco Laccetti, Antonello Belli, Gerardino Amato, Potito Di Muro, Olga Credendino, Alessandra Picardi, Piergiuseppe De Berardinis, Giovanna Del Pozzo, and Carmen Gianfrani more...
- Subjects
Infectious Diseases ,Virology - Abstract
Kidney transplanted recipients (KTR) are at high risk of severe SARS-CoV-2 infection due to immunosuppressive therapy. Although several studies reported antibody production in KTR after vaccination, data related to immunity to the Omicron (B.1.1.529) variant are sparse. Herein, we analyzed anti-SARS-CoV-2 immune response in seven KTR and eight healthy controls after the second and third dose of the mRNA vaccine (BNT162b2). A significant increase in neutralizing antibody (nAb) titers were detected against pseudoviruses expressing the Wuhan-Hu-1 spike (S) protein after the third dose in both groups, although nAbs in KTR were lower than controls. nAbs against pseudoviruses expressing the Omicron S protein were low in both groups, with no increase after the 3rd dose in KTR. Reactivity of CD4+ T cells after boosting was observed when cells were challenged with Wuhan-Hu-1 S peptides, while Omicron S peptides were less effective in both groups. IFN-γ production was detected in KTR in response to ancestral S peptides, confirming antigen-specific T cell activation. Our study demonstrates that the 3rd mRNA dose induces T cell response against Wuhan-Hu-1 spike peptides in KTR, and an increment in the humoral immunity. Instead, humoral and cellular immunity to Omicron variant immunogenic peptides were low in both KTR and healthy vaccinated subjects. more...
- Published
- 2023
- Full Text
- View/download PDF
46. 108P Safety results of post-neoadjuvant T-DM1 in the Italian compassionate use program (GIM26-TRASTHER study)
- Author
-
F. Poggio, M. Tagliamento, D. Favero, M. De Laurentiis, G. Tonini, A. Bernardo, E. Ferraris, I. Paris, F. Riccardi, G.V. Bianchi, G. Cancello, C. Chini, A. Fontana, G. Bisagni, A. Crippa, A. Gennari, R. Berardi, A. Musolino, M. Lambertini, and L. Del Mastro more...
- Subjects
Cancer Research ,Oncology - Published
- 2023
- Full Text
- View/download PDF
47. 83P Exoxomes and miRNA in breast cancer cancerogenesis: A case-control study
- Author
-
B. Cardinali, P. Piccioli, L. Zinoli, S. Coco, A. Sciutto, C. Bruzzo, Z. Cavalieri, G. Chiorino, P. Ostano, R. Tasso, R. Quarto, D. Ceresa, P. Malatesta, A. Rubagotti, F. Boccardo, and L. Del Mastro
- Subjects
Cancer Research ,Oncology - Published
- 2023
- Full Text
- View/download PDF
48. 101P Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: An individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
- Author
-
M. Lambertini, E. Blondeaux, G. Bisagni, S. Mura, S. de Placido, M. De Laurentiis, A. Fabi, A. Rimanti, A. Michelotti, M. Mansutti, A. Russo, F. Montemurro, A. Frassoldati, A. Durando, S. Gori, A. Turletti, S. Tamberi, Y. Urracci, E. de Azambuja, and L. Del Mastro more...
- Subjects
Cancer Research ,Oncology - Published
- 2023
- Full Text
- View/download PDF
49. 209P Trastuzumab plus lapatinib or chemotherapy in patients with HER2-positive advanced breast cancer refractory to anti-HER2 therapies: A randomized, multicenter, phase II trial (GIM12-TYPHER)
- Author
-
C. De Angelis, M. Pagliuca, T. Gamucci, M. Mansutti, Z. Ballatore, M. De Laurentiis, R. Bordonaro, A. Pazzola, V. Leonardi, D. Bruzzese, A.M. Mosconi, C. Molica, S. Cinieri, A. Fabi, L. Del Mastro, F. Puglisi, S. de Placido, M. Giuliano, and G. Arpino more...
- Subjects
Cancer Research ,Oncology - Published
- 2023
- Full Text
- View/download PDF
50. Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
- Author
-
Matteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, Silvia Mura, Sabino De Placido, Michelino De Laurentiis, Alessandra Fabi, Anita Rimanti, Andrea Michelotti, Mauro Mansutti, Antonio Russo, Filippo Montemurro, Antonio Frassoldati, Antonio Durando, Stefania Gori, Anna Turletti, Stefano Tamberi, Ylenia Urracci, Piero Fregatti, Maria Grazia Razeti, Roberta Caputo, Carmine De Angelis, Valeria Sanna, Elisa Gasparini, Elisa Agostinetto, Evandro de Azambuja, Francesca Poggio, Luca Boni, and Lucia Del Mastro more...
- Subjects
General Medicine - Published
- 2023
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.